ArticleEFSA journal. European Food Safety Authority2017
Lumpy skin disease: I. Data collection and analysis.
Article in EFSA journal. European Food Safety Authority, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- A systematic review of epidemiological modelling in response to lumpy skin disease outbreaks.Frontiers in veterinary science · 2024Pooled it
- Review
- Article
- Diagnostic approach, vaccination and treatment priorities for Lumpy Skin Disease in cattle: lessons from Balkan epidemics to Western Europe re-emergence (2025).Veterinary research communications · 2026Review
- Increased ruminoreticular temperature after simultaneous lumpy skin disease and foot-and-mouth disease vaccination in Hanwoo (Journal of veterinary science · 2026Article
- Epidemiological Study and Molecular Characterization of Lumpy Skin Disease in Cattle in Egypt.Veterinary medicine international · 2026Article
- Clinical and molecular description of natural infections with an Asian strain of lumpy skin disease virus in Bos indicus.Scientific reports · 2025Article
- Progress in diagnostic methods and vaccines for lumpy skin disease virus: a path towards understanding the disease.Veterinary research communications · 2025Review
- A poxvirus ankyrin protein LSDV012 inhibits IFIT1 in a host-species-specific manner by compromising its RNA binding ability.PLoS pathogens · 2025Article
- Prospective Case-Control Study of Determinants for African Swine Fever Introduction in Commercial Pig Farms in Poland, Romania, and Lithuania.Transboundary and emerging diseases · 2025Article
- Serological response to lumpy skin disease in recovered and clinically healthy vaccinated and unvaccinated cattle of Bangladesh.Frontiers in veterinary science · 2025Article
- Lumpy Skin Disease: Insights into Molecular Pathogenesis and Control Strategies.Veterinary sciences · 2024Review
- Susceptibility of Mediterranean Buffalo (Viruses · 2024Article
- Development of a Synthesized Gene Unique to Lumpy Skin Disease Virus and Its Application in Serological Differentiation of Naturally Infected from Vaccinated Cattle with Attenuated Goat Pox Vaccine.Transboundary and emerging diseases · 2024Article
- Persistence of passive immunity in calves receiving colostrum from cows vaccinated with a live attenuated lumpy skin disease vaccine and the performance of serological tests.Frontiers in veterinary science · 2024Article
- Review
- Article
- Article
- Duration of Immunity Induced after Vaccination of Cattle with a Live Attenuated or Inactivated Lumpy Skin Disease Virus Vaccine.Microorganisms · 2023Article
- Genetic analysis of genome sequence characteristics of two lumpy skin disease viruses isolated from China.BMC veterinary research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An epidemiological analysis of the temporal and spatial patterns of LSD epidemics and of the risk factors for LSD spread in south-eastern Europe was performed, based on the data collected from affected and at risk countries. Since 2015, the extent of the LSD epidemics in south-eastern Europe was over 7,600 LSD outbreaks with 12,800 affected animals, with most outbreaks occurring between May and August. Most LSD spread occurs over a relatively small distance, approximately between 10 and 20 km, and the speed of propagation was estimated to be mostly up 2 km/day, in agreement with the vector-borne pattern of LSD. Proximity to affected farms, warm temperatures and related vector abundance were among the main risk factors for LSD spread. Within a few months' at least 90% of the animal population had been vaccinated with live homologous vaccine against LSD in south-eastern Europe. Where almost total vaccination coverage was achieved, no further outbreaks were reported. The vaccination effectiveness in Albania was estimated to be around 70% at farm level and 77% at animal level. Possible adverse effects to live homologous vaccine, including fever, decreased milk production and oedema at injection site were reported in Croatia (a LSD-free country) mostly within 2 weeks after vaccination, in 0.09% of the vaccinated animals. Unique farm identifiers should be always used across all databases, so to allow further analysis especially on improving the mathematical models for more robust estimates of transmission parameters applicable to the region, and for better estimation of vaccination effectiveness. All suspected clinical cases in vaccinated animals should be confirmed by differentiating field virus from vaccine strain. Trapping surveys for estimation of vector abundance can be carried out by targeting some sentinel farms, to be followed up during the whole LSD season, while long-term studies can give more accurate information about species composition and seasonality of potential LSD vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.